Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways

Cancer Letters

Volumn 331, Issue 1, 2013, Pages 11-17

  Gimba, E R ^a,b   Tilli, T M ^b  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Alternative splicing; Clinical application; Functional roles; Osteopontin

Indexed keywords

ANTIBODY; OLIGONUCLEOTIDE; OSTEOPONTIN; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; AORTA VALVE DISEASE; BIOLOGICAL FUNCTIONS; BREAST CANCER; CALCIFIC AORTIC VALVE DISEASE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SHORT SURVEY; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA;

EID: 84873523452     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.003     Document Type: Review

References (57)

1. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64:7647-7654.
2. Douglas A.G., Wood M.J. RNA splicing: disease and therapy. Brief. Funct. Genomics 2011, 10:151-164.
3. Weidle U.H., Maisel D., Klostermann S., et al. Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics Proteomics 2011, 8:211-226.
4. Bellahcène A., Castronovo V., Ogbureke K.U., et al. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat. Rev. Cancer 2008, 8:212-226.
5. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Pre- and post-translational regulation of osteopontin in cancer. J. Cell Commun. Signal 2011, 5:111-122.
6. Manji S.S., Ng K.W., Martin T.J., Zhou H. Transcriptional and posttranscriptional regulation of osteopontin gene expression in preosteoblasts by retinoic acid. J. Cell Physiol. 1998, 176:1-9.
7. Singh K., Mukherjee A.B., De Vouge M.W., et al. Differential processing of osteopontin transcripts in rat kidney- and osteoblast-derived cell lines. J. Biol. Chem. 1992, 267:23847-23851.
8. Saavedra R.A., Kimbro S.K., Stern D.N., et al. Gene expression and phosphorylation of mouse osteopontin. Ann. NY Acad. Sci. 1995, 760:35-43.
9. Bissonnette N., Dudemaine P.L., Thibault C., Robitaille G. Proteomic analysis and immunodetection of the bovine milk osteopontin isoforms. J. Dairy Sci. 2012, 95:567-579.
10. Christensen B., Kazanecki C.C., Petersen T.E., et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J. Biol. Chem. 2007, 282:19463-19472.
11. Boskey A.L., Christensen B., Taleb H., Sørensen E.S. Post-translational modification of osteopontin: effects on in vitro hydroxyapatite formation and growth. Biochem. Biophys. Res. Commun. 2012, 419:333-338.
12. Sainger R., Grau J.B., Poggio P., et al. Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers 2012, 17:111-118.
13. Shinohara M.L., Kim H.J., Kim J.H., et al. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. USA 2008, 105:7235-7239.
14. He B., Mirza M., Weber G.F. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006, 25:2192-2202.
15. Mirza M., Shaughnessy E., Hurley J.K., et al. Osteopontin-c is a selective marker of breast cancer. Int. J. Cancer 2008, 122:889-897.
16. Christensen B., Petersen T.E., Sørensen E.S. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem. J. 2008, 411:53-61.
17. Arjomandi M., Frelinger J., Donde A., et al. Secreted osteopontin is highly polymerized in human airways and fragmented in asthmatic airway secretions. PLoS ONE 2011, 6:e25678.
18. Junaid A., Moon M.C., Harding G.E., Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am. J. Physiol. Cell Physiol. 2007, 292:C919-926.
19. Inoue M., Shinohara M.L. Intracellular osteopontin (iOPN) and immunity. Immunol. Res. 2011, 49:160-172.
20. Ivanov S.V., Ivanova A.V., Goparaju C.M., et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem. Biophys. Res. Commun. 2009, 382:514-518.
21. Courter D., Cao H., Kwok S., et al. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 2010, 5:e9633.
22. Blasberg J.D., Goparaju C.M., Pass H.I., Donington J.S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J. Thorac. Cardiovasc. Surg. 2010, 139:1587-1593.
23. Sullivan J., Blair L., Alnajar A., et al. Expression and regulation of nicotine receptor and osteopontin isoforms in human pancreatic ductal adenocarcinoma. Histol. Histopathol. 2011, 26:893-904.
24. Sullivan J., Blair L., Alnajar A., et al. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 2009, 146:232-240.
25. Tilli T.M., Franco V.F., Robbs B.K., et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol. Cancer Res. 2011, 9:280-293.
26. Tilli T.M., Mello K.D., Ferreira L.B., et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012, 10.1002/pros.22523.
27. Saitoh Y., Kuratsu J., Takeshima H., et al. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab. Invest. 1995, 72:55-63.
28. Takafuji V., Forgues M., Unsworth E., et al. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.
29. Chae S., Jun H.O., Lee E.G., et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int. J. Oncol. 2009, 35:1409-1416.
30. Yan W., Qian C., Zhao P., et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010, 12:765-775.
31. Goparaju C.M., Pass H.I., Blasberg J.D., et al. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J. Thorac. Oncol. 2010, 5:1516-1523.
32. Zhao B., Sun T., Meng F., et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J. Cancer Res. Clin. Oncol. 2011, 137:1061-1070.
33. Tilli T.M., Thuler L.C., Matos A.R., et al. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 2012, 92:13-19.
34. Grau J.B., Poggio P., Sainger R., et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann. Thorac. Surg. 2012, 93:79-86.
35. Wu J., Pungaliya P., Kraynov E., Bates B. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry. Biomarkers 2012, 17:125-133.
36. Hahnel A., Wichmann H., Greither T., et al. Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer 2012, 12:131.
37. Morimoto J., Sato K., Nakayama Y., et al. Osteopontin modulates the generation of memory CD8+ T cells during influenza virus infection. J. Immunol. 2011, 187:5671-5683.
38. Sabo-Attwood T., Ramos-Nino M.E., Eugenia-Ariza M., et al. Osteopontin modulates inflammation, mucin production, and gene expression signatures after inhalation of asbestos in a murine model of fibrosis. Am. J. Pathol. 2011, 178:1975-1985.
39. Braitch M., Constantinescu C.S. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm. Allergy Drug Targets 2010, 9:249-256.
40. Weber G.F., Zawaideh S., Hikita S., et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 2002, 72:752-761.
41. Ek-Rylander B., Flores M., Wendel M., et al. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J. Biol. Chem. 1994, 269:14853-14856.
42. Meng H., Lu C., Mabuchi H., Tanigawa N. Prognostic significance and different properties of surviving splicing variants in gastric cancer. Cancer Lett. 2003, 216:147-155.
43. Wu S., Reinhard G., Tillmann T., et al. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2005, 23:3038-3042.
44. Edberg D.D., Adkins J.N., Springer D.L., Reeves R. Dynamic and differential in vivo modifications of the isoform HMGA1a and HMGA1b chromatin proteins. J. Biol. Chem. 2005, 280:8961-8973.
45. Goehe R.W., Shultz J.C., Murudkar C., et al. HnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J. Clin. Invest. 2010, 120:3923-3939.
46. Cao Z., Dai J., Fan K., et al. A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol. Immunol. 2008, 45:3683-3692.
47. Christensen B., Nielsen M.S., Haselmann K.F., et al. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem. J. 2005, 390:285-292.
48. Yamaguchi Y., Hanashima S., Yagi H., et al. NMR characterization of intramolecular interaction of osteopontin, an intrinsically disordered protein with cryptic integrin-binding motifs. Biochem. Biophys. Res. Commun. 2010, 393:487-491.
49. Kazanecki C., Kowalski A.J., Ding T., et al. Characterization of anti-osteopontin monoclonal antibodies: binding sensitivity to post-translational modifications. J. Cell. Biochem. 2007, 102:925-935.
50. Layfield R., Bannister A.J., Pierce E.J., McDonald C.J. CDNA clones for mouse parotid proline-rich proteins. mRNA regulation by isoprenaline and the nucleotide sequence of proline-rich protein cDNA MP5. Eur. J. Biochem. 1992, 204:591-597.
51. Williamson M.P. The structure and function of proline-rich regions in proteins. Biochem. J. 1994, 297:249-260.
52. Barrie E.S., Smith R.M., Sanford J.C., Sadee W. MRNA transcript diversity creates new opportunities for pharmacological intervention. Mol. Pharmacol. 2012, 81:620-630.
53. Patani N., Jouhra F., Jiang W., Mokbel K. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 2008, 28:4105-4110.
54. Blair C.A., Zi X. Potential molecular targeting of splice variants for cancer treatment. Indian J. Exp. Biol. 2011, 49:836-839.
55. Watts J.K., Corey D.R. Silencing disease genes in the laboratory and the clinic. J. Pathol. 2012, 226:365-379.
56. Zhou J., Zheng X., Shen H. Targeting RNA-splicing for SMA treatment. Mol. Cells 2012, 33:223-228.
57. Spitali P., Aartsma-Rus A. Splice modulating therapies for human disease. Cell 2012, 148:1085-1088.